Spyre CFO exercises options, sells 7.5K shares
Spyre Therapeutics Chief Financial Officer Scott L. Burrows reported an option exercise and related stock sales.
Rhea-AI Filing Summary
Spyre Therapeutics Chief Financial Officer Scott L. Burrows reported an option exercise and related stock sales. On April 1, 2026, he exercised stock options to acquire 7,500 shares of common stock at an exercise price of $14.50 per share, fully using the remaining options covered in this filing.
On the same date, he sold 6,200 shares at a weighted average price of $49.21 and 1,300 shares at a weighted average price of $49.98 in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 97,994 shares of common stock, including 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,500 shares ($261K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Burrows Scott L
Role
Chief Financial Officer
Sold
7,500 shs ($370K)
Approx. gross sale proceeds
$370K
Approx. exercise cost
$109K
Approx. pre-tax spread
$261K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,500 | $14.50 | $109K |
| Sale | Common Stock | 6,200 | $49.21 | $305K |
| Sale | Common Stock | 1,300 | $49.98 | $65K |
Holdings After Transaction:
Stock Option (Right to Buy) — 394,857 contracts (Direct);
Common Stock — 97,994 shares (Direct)
Footnotes (5)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.69 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.76 to $50.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
- F5. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Options exercised: 7,500 shares at $14.50
Shares sold (block 1): 6,200 shares at $49.21
Shares sold (block 2): 1,300 shares at $49.98
+2 more
5 metrics
Options exercised
7,500 shares at $14.50
Stock option exercise on April 1, 2026
Shares sold (block 1)
6,200 shares at $49.21
Weighted average sale price on April 1, 2026
Shares sold (block 2)
1,300 shares at $49.98
Weighted average sale price on April 1, 2026
Shares held after transaction
97,994 shares
Direct common stock holdings after April 1, 2026 trades
Restricted stock units
67,476 RSUs
RSUs vesting in equal installments on Sept 1, 2026 and 2027
Key Terms
Rule 10b5-1 trading plan, restricted stock units ("RSUs"), weighted average price, reverse stock split, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units ("RSUs") financial
"Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.69 to $49.63, inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
reverse stock split financial
"shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023)"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
stock option (Right to Buy) financial
"This option represents a right to purchase 404,857 shares of the Issuer's common stock"
FAQ
What insider transactions did Spyre Therapeutics (SYRE) report for its CFO?
Spyre Therapeutics reported that CFO Scott L. Burrows exercised stock options for 7,500 shares at $14.50 per share, then sold 6,200 shares at a weighted average of $49.21 and 1,300 shares at $49.98 in open-market trades on April 1, 2026.
Was the Spyre Therapeutics (SYRE) CFO’s stock sale part of a Rule 10b5-1 plan?
Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2025. Such plans pre-schedule trades, making the timing more routine and less tied to short-term information about Spyre Therapeutics’ business.
What are the terms of the Spyre Therapeutics (SYRE) CFO’s restricted stock units?
The CFO holds 67,476 restricted stock units, each representing a contingent right to receive one share of common stock. These RSUs vest in two equal installments on September 1, 2026 and September 1, 2027, subject to his continued employment with Spyre Therapeutics.
How were the Spyre Therapeutics (SYRE) CFO’s sale prices calculated in the Form 4?
The reported sale prices are weighted averages. The 6,200 shares were sold in multiple trades between $48.69 and $49.63, and the 1,300 shares between $49.76 and $50.15. Detailed per-trade pricing is available on request from the company or the SEC.
AI-generated analysis. How Rhea-AI works. Not financial advice.
